Product information
About Jyseleca®
Consult Jyseleca® (filgotinib) product information and the Summary of Product Characteristic on the European Medicines Agency’s website
Welcome to our Products page. You will find more details about where to find product information, and how to contact us in relation to our medicines
Prescription medicines
Our medicines are approved in individual countries for specific uses and the information we can provide for patients is governed by local regulations.
We cannot provide detailed information about our prescription medicines on this website, in compliance with regulations. In some cases, health care professionals and patients can visit local Galapagos websites to find out more about our medicine and products in developments.
In some countries we cannot provide any information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.
Product information
Consult Jyseleca® (filgotinib) product information and the Summary of Product Characteristic on the European Medicines Agency’s website
Medicine safety
If you experienced or became aware of an adverse event related to Jyseleca®, please report these as soon as possible by contacting our Drug Safety Team
Medical information
For medical information inquiries regarding Galapagos products, please contact us by mail or dial 00800 7878 1345
Medical information
For medical information inquiries regarding Galapagos products, contact us by telephone dialing from Belgium, Luxembourg, the Netherlands, France, Spain, Italy, Germany, Republic of Ireland, Norway, Sweden, Finland, Denmark or Austria: 00800 7878 1345.
For medical information inquiries regarding Galapagos products in Great Britain and Northern Ireland: 0800 072 7878.
Pharmacovigilance
Medicines can cause side effects. The majority of these are identified at the clinical investigation stages and can be found in the ‘Summary of product characteristics’, the package leaflet of a medicine.
Galapagos consistently collates and reviews product safety information received from clinical trials and post-marketing activities. The information received is evaluated on an ongoing basis, ensuring a continuing safety surveillance of our products.
If you experienced or became aware of an adverse event related to Jyseleca®, please report these as soon as possible.
Important Note: Patients should always ask their physician for medical advice as soon as possible when confronted with adverse events.
Product quality
If you wish to report a product quality complaint related to our medicinal product please dial the following numbers: